TABLE 4.
Percentage of California C. botulinum strains inhibited across a range of MICs of SXT compared to percent inhibition reported by Swenson et al.
| Study | Cumulative % C. botulinum strains inhibited by SXT with MIC (μg/ml)a of: |
||||||
|---|---|---|---|---|---|---|---|
| ≤0.50 | ≤1 | ≤2 | ≤4 | ≤8 | ≤16 | ≤32 | |
| Swenson et al. (6) (n = 224)b | 13 | 17 | 19 | 100 | |||
| This study (n = 260)c | 63 | 69 | 75 | 78 | 79 | 80 | 100 |
a
Concentration represents concentration of trimethoprim; trimethoprim and sulfamethoxazole were present at a ratio of 1/19.
b
Study included C. botulinum types A to G, at n = 109, 65, 5, 1, 32, 11, and 1, respectively, isolated from human feces, wounds, and a variety of food sources. MICs were determined by the agar dilution method on WCA supplemented with 5% LHB.
c
Study included C. botulinum types A and B, Ba, Bf, and C. baratii type F, at n = 156, 89, 12, 2, and 1, respectively. All strains isolated from feces of individual infant botulism patients. MICs were determined by Etest method on BMH.